Novartis pays big fine for bribing doctors in the US
The Novartis offices in Basel, Switzerland.
Keystone / Georgios Kefalas
Swiss pharma company Novartis will pay $729 million (CHF688 million) to US authorities in an out-of-court settlement over various charges, including that the company bribed doctors to use its drugs.
This content was published on
2 minutes
Keystone-SDA/dos
Audrey Strauss, the acting Manhattan US Attorney, said the firm had paid out for “speaking fees, exorbitant meals, and top-shelf alcohol that were nothing more than bribes to get doctors across the country to prescribe Novartis’s drugs.”
Essentially, Novartis admitted to having organised thousands of lavish conferences and events ostensibly aimed at “further education”. Guest speakers were paid large amounts to attend.
In return, the doctors were incentivised to prescribe Novartis products, such as drugs for high blood pressure and diabetes, which were then reimbursed by state health authorities.
“Not only did Novartis incentivise doctors to host these speaking events, reps bribed the doctors to write more prescriptions of the company’s drugs to give Novartis an advantage over competitors within their field,” said William F Sweeney Jr, head of New York’s FBI office.
“Greed replaced the responsibility the public expects from those who practice medicine.”
As part of the agreement with US authorities, Novartis has signed a five-year code of good conduct. The Basel-based firm also said on Thursday that it was revising its methods of providing medical training, notably by planning more online webinars.
In a statement, Novartis CEO Vas Narasimhan said that the company had already changed (the charges in question were raised by a whistle-blower in 2011) and that it had “new leadership, a stronger culture, and a more comprehensive commitment to ethics”.
“With these agreements we mark an important milestone on our journey to build trust with society as we continue re-imagining medicine to improve and extend lives all around the world,” Narasimhan said.
A week ago Novartis and two of its subsidiaries admitted to further bribery schemes involving dealings in Vietnam and Greece, and agreed to pay some $347 million to settle US investigations.
As of Thursday, the stock market has not reacted particularly strongly: the Novartis share price dropped 0.8%, around the same as its competitor Roche.
Popular Stories
More
Culture
Wealth is not all: how gentrification in Zurich has led to housing shortage
Is reforming the Swiss pension system still possible, and if so, how?
Solutions still need to be found to meet the challenge of an ageing population and to improve the pensions of low-paid workers, the majority of whom are women.
Job prospects remain good in Switzerland – apart from in Ticino
This content was published on
Employment prospects remain positive in Switzerland as a whole, but they are negative in southern Italian-speaking canton Ticino.
This content was published on
In an international comparison, Swiss adults perform above average in the basic skills of reading, everyday math and problem solving.
New carrier particle discovered for transporting drugs in body
This content was published on
Researchers at the federal technology institute ETH Zurich have discovered particles that can be used to deliver drugs precisely, for example to a cancerous tumour in the body.
Swiss parliament clears way for new start with e-ID
This content was published on
A new attempt to introduce electronic proof of identity has been made in Switzerland. The Senate has resolved the final differences in the legal provisions on a state e-ID.
Sixteen-day Swiss campaign against gender-based violence ends
This content was published on
The 16-day campaign against gender-based violence came to an end on Tuesday. Several hundred organizations mobilized across Switzerland during this period.
Swiss parliament wants CHF15 million for women’s Euro 2025
This content was published on
Parliament wants Switzerland to support next year's European Women's Football Championship with CHF15 million ($17 million).
Rare Roman coin auctioned for almost CHF2 million in Geneva
This content was published on
A rare Roman coin with a portrait of Brutus, the assassin of Julius Caesar, was sold at a Geneva auction on Monday for CHF1.89 million ($2.15 million), according to the organiser of the sale.
Swiss Senate approves federal budget without opposition
This content was published on
The Swiss army will receive an additional CHF530 million in 2025, and no cuts will be made to direct payments for agriculture. What is unclear is how much will be saved on foreign aid.
Swiss suspend decisions on asylum-seekers from Syria
This content was published on
Asylum procedures and decisions for asylum-seekers from Syria will be suspended with immediate effect until the situation can be reassessed, the State Secretariat for Migration (SEM) said.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Novartis CEO warns that data on Covid-19 drugs is missing
This content was published on
Potential pharmaceutical solutions to combat Covid-19 must have strong clinical data to back their efficacy, according to Novartis boss Vasant Narasimhan.
US Senate asks Novartis to shed light on data manipulation allegations
This content was published on
The Swiss pharmaceutical firm Novartis has been asked to provide details regarding possible data inaccuracies for its human gene therapy Zolgensma.
Swiss pharma giants swallow up start-ups in push for next big gene therapy
This content was published on
Swiss drug makers are increasingly relying on buying science rather than doing it themselves in the search for the next big medical breakthrough.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.